Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

The microRNA miR-23b suppresses IL-17-associated autoimmune inflammation by targeting TAB2, TAB3 and IKK-α
Phase II Cladribine Add-on to Interferon-beta (IFN-b) Therapy in MS Subjecs With Active Disease (ONWARD)
Cardiotoxicity of mitoxantrone treatment in a german cohort of 639 multiple sclerosis patients.
Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis.
Effects of rituximab on lymphocytes in multiple sclerosis and neuromyelitis optica.
Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study.
Epigenetic changes in patients with multiple sclerosis.
Effect of lipoic acid consumption on oxidative stress among multiple sclerosis patients: A randomized controlled clinical trial.
Rituximab in Steroid-Dependent or Frequently Relapsing Idiopathic Nephrotic Syndrome.
Autologous attenuated T-cell vaccine (Tovaxin) dose escalation in multiple sclerosis relapsing-remitting and secondary progressive patients nonresponsive to approved immunomodulatory therapies.
Overcoming barriers in progressive multiple sclerosis research.
Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis.
Saccadic intrusions: review and update.
Dalfampridine sustained-release for symptomatic improvement of walking speed in patients with multiple sclerosis.
Normal-appearing white matter in multiple sclerosis is in a subtle balance between inflammation and neuroprotection.
Mechanisms of neurodegeneration shared between multiple sclerosis and Alzheimer's disease.
The multiple sclerosis rating scale, revised (MSRS-R): Development, refinement, and psychometric validation using an online community.
Modeling probability of additional cases of natalizumab-associated JCV sero-negative progressive multifocal leukoencephalopathy.
A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) (LIBRETTO)
Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis.
US top court denies Israel's Teva Pharmaceuticals stay in Copaxone patent fight
Extoxnet (extension toxicology network), 4-aminopyridine
Regional Susceptibility to TNF-α Induction of Murine Brain Inflammation via Classical IKK/NF-κB Signalling.
Receptos Reports Positive Phase 2 Results for TOUCHSTONE Trial of RPC1063 in Ulcerative Colitis
Rescue Therapy Using Rituximab for Multiple Sclerosis.

Pages